Biodesix raises additional series E financing
13 January 2015 | By Biodesix, Inc.
Biodesix, Inc., announced that the company increased the size of its offering of series E preferred shares in a follow-on sale...
List view / Grid view
News
Roche, Meiji and Fedora join forces to tackle increasing bacterial resistance to antibiotics
13 January 2015 | By Roche
Roche, Meiji Seika Pharma (Meiji) and Fedora announced that they have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development...
MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology
13 January 2015 | By Astrazeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses...
ORYZON appoints Greg Weaver as Global Chief Financial Officer
12 January 2015 | By Oryzon
Oryzon Genomics SA, a clinical stage biopharmaceutical company developing therapeutics in oncology and CNS diseases based on its proprietary epigenetics technology platform, announced the appointment of Gregory L. Weaver as Executive Vice President and Chief Financial Officer, effective January 12, 2015...
Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology
12 January 2015 | By Roche
Collaboration leverages both companies’ strengths to advance the progress of personalized treatments for patients with cancer...
Kymab partners with cancer immunotherapy expert on anti-cancer therapeutics
12 January 2015 | By Kymab
Combination of Kymab’s unique antibody platform and cytokine technologies expected to deliver enhanced efficacy and tolerability...
FDA approves Roche’s cobas® TaqScreen MPX Test, v2.0 for use in the detection and identification of HIV, HCV, and HBV
9 January 2015 | By Roche
FDA Approves Roche’s Blood Screening Assay for Simultaneous Detection and Identification of Three Major Viral Targets. cobas TaqScreen MPX Test, v2.0 offers enhanced sensitivity and workflow advantages...
Protagen AG appoints Bernhard Kirschbaum as new Board Member
8 January 2015 | By PROTAGEN AG
PROTAGEN AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics (CDx) in the autoimmune field, announced that the former Head of Research and Early Development of Merck Serono, Dr. Bernhard Kirschbaum, has joined the company’s Supervisory Board...
Oxford Global Conferences received excellent feedback from the 2014 Drug Discovery USA Congress
8 January 2015 | By Oxford Global Conferences
Oxford Global Conferences were proud to present the Drug Discovery USA Congress this October in Boston, USA...
SciFluor Life Sciences awarded U.S. Patent for KCNQ2/3 activator designed for treatment of epilepsy and related neurological disorders
8 January 2015 | By SciFluor Life Sciences
SciFluor Life Sciences, LLC, an emerging clinical stage biopharmaceutical company that creates innovative therapeutics for patients with ophthalmologic and neurologic disease, announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,916,133 with claims covering the novel compound SF0034...
AAA fully acquires Atreus Pharmaceuticals; enrolls first patient in a Phase I/II clinical trial for Annexin V-128
8 January 2015 | By Advanced Accelerator Applications S.A.
Advanced Accelerator Applications S.A. announced that it has acquired the remaining 49.9% of Atreus Pharmaceuticals Corporation, a development-stage biopharmaceutical company headquartered in Ottawa, Canada...
UK patients with moderately to severely active ulcerative colitis gain access to a range of biologic therapies on the NHS
8 January 2015 | By MSD
NICE says ‘yes’ to REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI® (golimumab) for adult patients with moderately to severely active ulcerative colitis...
TxCell receives EU Orphan Drug Designation for Col-Treg in the treatment of non-infectious uveitis
6 January 2015 | By TxCell
TxCell SA (FR0010127662 – TXCL) announces that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis...
Trial finds cancer drug can block key signal in cancer growth and drug resistance
6 January 2015 | By The Institute of Cancer Research
An experimental cancer drug may block an important driver for the survival, growth and spread of cancer cells...
Pfizer acquires Redvax GmbH
5 January 2015 | By Pfizer
Acquisition provides Pfizer with a preclinical CMV vaccine candidate...